Persistence. It cannot be excluded that bendroflumethiazide is persistent, due to the lack of data.
Bioaccumulation. It cannot be excluded that bendroflumethiazide bioaccumulates, due to the lack of data.
Toxicity. It cannot be excluded that bendroflumethiazide is toxic, due to the lack of data.
Risk. Risk of environmental impact of bendroflumethiazide cannot be excluded, due to the lack of environmental toxicity.
This summary information comes from Fass. Manufacturer has on fass.se stated that data about the environmental impact is missing for the substance so that the environmental risk cannot be calculated. It is voluntary for manufacturers to provide information on the environmental impact on fass.se.
Fass environmental information
Fass environmental information for Salures (bendroflumethiazide) from Pfizer (downloaded 2022-04-20).
Persistence: No data.
Bioaccumulation: No data.
Toxicity: No data.
Risk of environmental impact of bendroflumethiazide cannot be excluded, due to the lack of environmental toxicity.
Pharmaceuticals residues in the aquatic environment in Region Stockholm
Bendroflumethiazide has previously been included in screening programs and measured in the aquatic environment in Region Stockholm.
- Fass för vårdpersonal.
- European Medicines Agency, EMA: Committee for Medicinal Products for Human Use (CHMP). Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use. 1 June 2006.
- Stockholm Vatten. Läkemedelsrester i Stockholms vattenmiljö. 2010. ISBN 978-91-633-6642-0.
- Provtagningar av läkemedelsrester i vatten, sediment och fisk för Region Stockholm.
Author: Health and Medical Care Administration, Region Stockholm